Multiple Dose Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antiretroviral Activity of MK-4646 Monotherapy in Antiretroviral Therapy-Naïve Participants With HIV-1
Latest Information Update: 04 Sep 2025
At a glance
- Drugs MK 4646 (Primary)
- Indications HIV-1 infections
- Focus Adverse reactions; Pharmacodynamics
- Sponsors Merck Sharp & Dohme
Most Recent Events
- 04 Sep 2025 Last checked against ClinicalTrials.gov record.
- 16 Jul 2025 Status changed from not yet recruiting to recruiting.
- 04 Jul 2025 New trial record